BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • August 2023
  • July 2023
  • May 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2017
  • March 2014
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Subscribe

BioTech Health X

43 posts

UncategorizedAlterome Therapeutics Strengthens Leadership Team with Appointment of Renowned Oncologist Dr. Andrew S. Chi as Chief Medical Officer

  • BioTech Health X
  • August 23, 2023
August 23, 2023 Alterome Therapeutics, Inc., a frontrunner in precision oncology, has announced the addition of Dr. Andrew…
0 Shares
0
0
0
0
0
0
0

Uncategorized11/19/21

  • BioTech Health X
  • May 30, 2023
BioTech Health X Ortho Clinical Diagnostics Overview & Q&A Michael S. Iskra, Executive Vice President of Commercial Excellence…
0 Shares
0
0
0
0
0
0
0
Welcome To BioTech Health X

Biotech NewsWelcome To BioTech Health X

  • BioTech Health X
  • May 26, 2023
The New Leader in BioTech News, BioTech Stock Information & BioTech Industry Analysis BioTech Health X delivers the…
0 Shares
0
0
0
0
0
0
0
Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data

Biotech NewsRecent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data

  • BioTech Health X
  • May 9, 2023
A recent report published by the American Association for Cancer Research titled Subgroup Analyses in Oncology Trials: Regulatory…
0 Shares
0
0
0
0
0
0
0
Virios-Therapeutics-Stock-Plunges-70-on-Fibromyalgia-Clinical-Trial-Failure-Results

Biotech NewsVirios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results

  • BioTech Health X
  • September 19, 2022
In a shocking failure, Virios Therapeutics announced this morning pre-market that topline results from its FORTRESS (Fibromyalgia Outcome…
1 Shares
1
0
0
0
0
0
0
CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

Biotech NewsCEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

  • BioTech Health X
  • September 10, 2022
CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor…
21 Shares
21
0
0
0
0
0
0
Mayo-Clinic-Gene-Accelerator

Biotech NewsMayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator

  • BioTech Health X
  • August 31, 2022
Mayo Clinic, Hibiscus BioVentures (Hibiscus), and Innoforce have announced the formation of Mayflower BioVentures, a cell and gene…
0 Shares
0
0
0
0
0
0
0
Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial

Biotech NewsKrystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial

  • BioTech Health X
  • August 1, 2022
Leader in redosable gene therapy Krystal Biotech, Inc. (NASDAQ: KRYS) announced today the United States Food and Drug…
7 Shares
6
1
0
0
0
0
0
ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug

Biotech NewsImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug

  • BioTech Health X
  • July 28, 2022
In breaking news, clinical-stage biotechnology company ImmunityBio, Inc. (NASDAQ: IBRX) has announced acceptance by the FDA review of…
1 Shares
1
0
0
0
0
0
0
Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement

Biotech NewsBrickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement

  • BioTech Health X
  • July 20, 2022
Clinical-stage pharmaceutical company Brickell Biotech, Inc. (Nasdaq: BBI) announced that the company has received formal notice from The…
1 Shares
1
0
0
0
0
0
0
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

  • BioTech Health X
  • July 20, 2022
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
4 Shares
4
0
0
0
0
0
0

Biotech InfoWhat is Biotechnology: Types, Examples and Applications

  • BioTech Health X
  • June 24, 2022
Understanding biotechnology Biotech involves studying organism functions at the molecular level and is often combined with many different…
0 Shares
0
0
0
0
0
0
0
Ocugen Announces FDA Clinical Hold Removal for Phase 2:3 COVAXIN BBV152 Clinical Trial

Biotech NewsOcugen Announces FDA Clinical Hold Removal for Phase 2/3 COVAXIN (BBV152) Clinical Trial

  • BioTech Health X
  • May 23, 2022
Biotechnology company Ocugen, Inc. (NASDAQ: OCGN) announced today that the U.S. Food and Drug Administration (FDA) has removed…
3 Shares
2
1
0
0
0
0
0
EF Hutton Initiates Coverage of Cel-Sci CVM with 17 Price Target Ahead of Rumored News

Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News

  • BioTech Health X
  • April 7, 2022
Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…
22 Shares
22
0
0
0
0
0
0
Legend Biotech Appoints Dr Guowei Fang Head of Global Research and Early Development

Biotech NewsLegend Biotech Appoints Dr. Guowei Fang As Head of Global Research and Early Development

  • BioTech Health X
  • April 1, 2022
Global biotechnology company Legend Biotech Corporation (NASDAQ: LEGN) announced today that Guowei Fang, Ph.D. will take over as…
28 Shares
27
1
0
0
0
0
0
2seventy-bio-Secure-170-Million-Extending-Cash-Runway-Into-2025

Biotech News2seventy bio Secure $170 Million Extending Cash Runway Into 2025

  • BioTech Health X
  • March 16, 2022
2seventy bio (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that it has agreed to sell…
9 Shares
8
1
0
0
0
0
0
Inhibikase-Therapeutics-Present-Phase-1-1b-Trial-Results-ADPD-Alzheimers-Parkinsons-Diseases-Conference

Biotech NewsInhibikase Therapeutics To Present Phase 1/1b Trial Results at AD/PD Alzheimer’s & Parkinson’s Diseases Conference

  • BioTech Health X
  • March 8, 2022
Clinical-stage pharmaceutical company Inhibikase Therapeutics, Inc. (Nasdaq: IKT) recently announced that President and CEO Dr. Milton Werner, Ph.D. will be…
12 Shares
11
1
0
0
0
0
0
Celyad-Oncology-Pauses-CYAD-101-002-Keynote-B79-Phase-1-Trial-After-2-Deaths-Reported

Biotech NewsCelyad Oncology Pauses CYAD-101-002 (Keynote-B79) Phase 1 Trial After 2 Deaths Reported

  • BioTech Health X
  • February 28, 2022
Clinical-stage biotechnology company Celyad Oncology (NASDAQ: CYAD) recently announced that the company has voluntarily paused the CYAD-101-002 (KEYNOTE-B79)…
8 Shares
8
0
0
0
0
0
0
Recent Posts
  • Alterome Therapeutics Strengthens Leadership Team with Appointment of Renowned Oncologist Dr. Andrew S. Chi as Chief Medical Officer
  • Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • 11/19/21
  • Welcome To BioTech Health X
  • Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
Recent Comments
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz MichaƂowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • August 23, 2023
    Alterome Therapeutics Strengthens Leadership Team with Appointment of Renowned Oncologist Dr. Andrew S. Chi as Chief Medical Officer
    • July 14, 2023
    Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
    Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
    • May 30, 2023
    11/19/21
    • May 26, 2023
    Welcome To BioTech Health X
    Welcome To BioTech Health X
    • May 9, 2023
    Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
    Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
Recent Posts
  • BenchSci Expands Advisory Board with New Pharma R&D Leaders
    BenchSci Expands Advisory Board with New Pharma R&D Leaders
    • April 21, 2022
  • Cellarity-Expands-Leadership-Team-to-Continue-Evolution-of-Breakthrough-Platform-to-Encode-Biology-and-Purposefully-Create-New-DrugsCellarity-Expands-Leadership-Team
    Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
    • February 10, 2022
  • BioTech Health X CEO Series Virios Therapeutics Greg Duncan
    BioTech Health X CEO Series: Virios Therapeutics Greg Duncan
    • February 1, 2022
Categories
  • BioTech CEO Interviews (4)
  • Biotech Info (1)
  • Biotech News (44)
  • Uncategorized (2)
BioTech Health X
Designed & Developed by BioTech Health X
  • Our Contributors
  • List of Modern Life Science Technologies
  • Contact Us

Subscribe to
Our Updates

Back to top